title: [Are there innovations in the treatment of Parkinson's disease?].
abstract: In the group of medication acting on the dopaminergic system the transdermal application of a dopamine agonist (Rotigotine) and a new MAO B inhibitor (Rasigiline) are receiving most attention. With some concern we had to learn that pergolide, a potent dopamine agonist, may be the cause of clinically relevant valvulopathies. Our possibilities to act on non-dopaminergic deficits is still very limited. The studies demonstrating a positive effect of cholinesterase inhibitors on cognitive decline are at least a positive signal.
authors.affiliation: Neurologie FMH, St. Gallen.
authors.forename: H P
authors.initials: HP
authors.lastname: Ludin
mesh_terms: D000978:Antiparkinson Agents / Q000009:adverse effects; D002188:Cannabis; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D018849:Controlled Clinical Trials as Topic; D018491:Dopamine Agonists / Q000009:adverse effects / Q000627:therapeutic use; D006349:Heart Valve Diseases / Q000139:chemically induced; D006801:Humans; D007189:Indans / Q000008:administration & dosage / Q000627:therapeutic use; D007980:Levodopa / Q000008:administration & dosage / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D010479:Pergolide / Q000009:adverse effects; D048448:Phenylcarbamates / Q000627:therapeutic use; D010919:Placebos; D000068836:Rivastigmine; D013997:Time Factors
chemical_list: D000978:Antiparkinson Agents; D002800:Cholinesterase Inhibitors; D018491:Dopamine Agonists; D007189:Indans; D008996:Monoamine Oxidase Inhibitors; D018696:Neuroprotective Agents; D048448:Phenylcarbamates; D010919:Placebos; C031967:rasagiline; D010479:Pergolide; D007980:Levodopa; D000068836:Rivastigmine